Naproxen sodium; sumatriptan succinate - Generic Drug Details

What are the generic drug sources for naproxen sodium; sumatriptan succinate and what is the scope of patent protection?

Naproxen sodium; sumatriptan succinate is the generic ingredient in two branded drugs marketed by Aurobindo Pharma Ltd, Rising, Sun Pharm, and Currax, and is included in four NDAs. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Naproxen sodium; sumatriptan succinate has sixteen patent family members in fourteen countries.

Five suppliers are listed for this compound.

Summary for naproxen sodium; sumatriptan succinate

International Patents:	16
US Patents:	1
Tradenames:	2
Applicants:	4
NDAs:	4
Finished Product Suppliers / Packagers:	5
Clinical Trials:	11
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for naproxen sodium; sumatriptan succinate
DailyMed Link:	naproxen sodium; sumatriptan succinate at DailyMed

Recent Clinical Trials for naproxen sodium; sumatriptan succinate

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
The Second Affiliated Hospital of Kunming Medical University	Phase 3
Second Hospital of Jilin University	Phase 3
Beijing Friendship Hospital	Phase 3

See all naproxen sodium; sumatriptan succinate clinical trials

Pharmacology for naproxen sodium; sumatriptan succinate

Drug Class	Nonsteroidal Anti-inflammatory Drug Serotonin-1b and Serotonin-1d Receptor Agonist
Mechanism of Action	Cyclooxygenase Inhibitors Serotonin 1b Receptor Agonists Serotonin 1d Receptor Agonists

Anatomical Therapeutic Chemical (ATC) Classes for naproxen sodium; sumatriptan succinate

G02CC	Antiinflammatory products for vaginal administration
G02C	OTHER GYNECOLOGICALS
G02	OTHER GYNECOLOGICALS
G	Genito-urinary system and sex hormones

M01AE	Propionic acid derivatives
M01A	ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
M01	ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
M	Musculo-skeletal system

M02AA	Antiinflammatory preparations, non-steroids for topical use
M02A	TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN
M02	TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN
M	Musculo-skeletal system

N02CC	Selective serotonin (5HT1) agonists
N02C	ANTIMIGRAINE PREPARATIONS
N02	ANALGESICS
N	Nervous system

Paragraph IV (Patent) Challenges for NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TREXIMET	Tablets	naproxen sodium; sumatriptan succinate	500 mg/85 mg	021926	1	2008-07-23

US Patents and Regulatory Information for naproxen sodium; sumatriptan succinate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Aurobindo Pharma Ltd	SUMATRIPTAN AND NAPROXEN SODIUM	naproxen sodium; sumatriptan succinate	TABLET;ORAL	207457-001	Feb 15, 2018	AB	RX	No	No
Currax	TREXIMET	naproxen sodium; sumatriptan succinate	TABLET;ORAL	021926-002	May 14, 2015		DISCN	Yes	No	7,332,183*PED				Y
Currax	TREXIMET	naproxen sodium; sumatriptan succinate	TABLET;ORAL	021926-001	Apr 15, 2008	AB	RX	Yes	Yes	7,332,183*PED				Y

Expired US Patents for naproxen sodium; sumatriptan succinate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Currax	TREXIMET	naproxen sodium; sumatriptan succinate	TABLET;ORAL	021926-002	May 14, 2015	5,872,145*PED
Currax	TREXIMET	naproxen sodium; sumatriptan succinate	TABLET;ORAL	021926-001	Apr 15, 2008	6,586,458*PED
Currax	TREXIMET	naproxen sodium; sumatriptan succinate	TABLET;ORAL	021926-002	May 14, 2015	6,060,499*PED

International Patents for naproxen sodium; sumatriptan succinate

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2004060355
European Patent Office	1575566	FORMES GALENIQUES MULTICOUCHES CONTENANT DE NAPROXENE ET DES TRIPTANES (MULTILAYER DOSAGE FORMS CONTAINING NAPROXEN AND TRIPTANS)
Austria	546134

Supplementary Protection Certificates for naproxen sodium; sumatriptan succinate

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0984957	CR 2012 00035	Denmark		PRODUCT NAME: ET KOMBINATIONSPRODUKT AF NAPROXEN OG ESOMEPRAZOL MAGNESIUM TRIHYDRAT; NAT. REG. NO/DATE: 49583 20120327; FIRST REG. NO/DATE: GB PL 17901/0263-001 20101105
0984957	PA2011005	Lithuania		PRODUCT NAME: NAPROXENUM + ESOMEPRAZOLUM; REGISTRATION NO/DATE: LT/1/10/2302/001-LT/1/10/2302/012 20110126
1411900	300481	Netherlands		PRODUCT NAME: NAPROXEN EN ESOMEPRAZOL; NATIONAL REGISTRATION NO/DATE: RVG 106235 20101118; FIRST REGISTRATION: GB PL 17901/0263-001 20101105

Market Dynamics and Financial Trajectory for Naproxen Sodium and Sumatriptan Succinate

Last updated: February 13, 2026

What Are the Current Market Sizes and Growth Trends?

Naproxen Sodium: The global NSAID market, including naproxen sodium, was valued at approximately $8.1 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of around 3.5% from 2023 through 2030, reaching an estimated $10.4 billion.

Sumatriptan Succinate: The global triptan market, dominated by sumatriptan succinate, was valued at roughly $2.8 billion in 2022. Forecasts indicate a CAGR of 4.2% until 2030, pushing its valuation close to $3.7 billion by 2030.

How Do Market Drivers Differ Between These Drugs?

Naproxen Sodium:

• Increasing prevalence of osteoarthritis, rheumatoid arthritis, and general musculoskeletal pain, especially in aging populations.
• Over-the-counter (OTC) availability in many markets drives volume sales.
• Rising awareness of pain management options supports demand, despite competition from other NSAIDs.

Sumatriptan Succinate:

• Growing incidence of migraines globally, with estimates of 1 billion people affected worldwide.
• Preference for targeted therapies over opioids and overuse of preventive medications.
• Strong prescription and branded medication pipelines support steady purchase volumes.

What Are the Key Challenges and Competitive Pressures?

Naproxen Sodium:

• Safety concerns related to cardiovascular risks, especially with prolonged use.
• Competition from other NSAIDs such as ibuprofen and COX-2 inhibitors.
• Shift towards prescription-only models in some regions may reduce OTC sales.

Sumatriptan Succinate:

• Availability of alternative triptans (e.g., rizatriptan, eletriptan) offering similar or improved efficacy.
• Potential entry of generic versions lowers prices and compresses margins.
• Limited scope for innovation as oral formulations dominate; intranasal and injectable forms face market penetration barriers.

How Does Patent Expiry Impact Long-term Revenue Models?

• Naproxen Sodium: Many OTC formulations are off-patent; generic variants dominate, leading to price competition.
• Sumatriptan Succinate: Patented formulations expired in the early 2000s; generics constitute a significant market share, depressing prices but expanding volume.

How Are Regulatory and Policy Developments Influencing Market Dynamics?

• FDA warnings on NSAIDs for cardiovascular and gastrointestinal risks influence prescribing patterns.
• EMA and FDA approvals for new formulations, like nasal sprays or transdermal patches, aim to diversify delivery methods.
• Growing emphasis on prescription surveillance and usage monitoring impacts sales strategies.

What Are the Investment and R&D Trends Indicating Future Growth?

• R&D investments in formulation innovations, such as extended-release NSAIDs and less risky triptan variants, continue.
• Partnerships between pharma companies and biotechnology firms aim to develop personalized pain and migraine therapies.
• Focus on digital health tools for migraine tracking and pain management enhances product value propositions.

What Is the Financial Outlook for Companies Holding Market Shares?

Drug/Market Segment	2022 Value	Projected 2030 Value	CAGR	Key Players
Naproxen Sodium	$8.1B	$10.4B	3.5%	Johnson & Johnson, Bayer, Walgreens (OTC)
Sumatriptan Succinate	$2.8B	$3.7B	4.2%	Merck (Imitrex), Teva, Novartis

Major players in naproxen sodium include Johnson & Johnson and Bayer, leveraging OTC availability. Sumatriptan succinate has branded dominance by Merck, with leading generics from Teva and Novartis.

Summary

The naproxen sodium market remains stable, driven by aging populations and OTC sales, but faces safety and competition issues. Sumatriptan succinate sustains growth through rising migraine prevalence and expanding formulations, despite commoditization via generics. Both markets are influenced by regulatory efforts and innovation pipelines, shaping their long-term financial trajectories.

---

Key Takeaways

• Naproxen sodium's market is valued at $8.1 billion in 2022, growing modestly due to OTC sales and safety concerns.
• Sumatriptan succinate’s market stood at $2.8 billion, with stronger growth prospects driven by migraine incidence.
• Patent expirations have increased generic competition, lowering prices but boosting volume.
• Formulation developments and digital health integrations present future growth avenues.
• Regulatory pressures influence prescribing and sales, with companies prioritizing innovative delivery methods.

---

FAQs

1. How does OTC availability affect naproxen sodium’s market?
OTC status enables broad consumer access, leading to high volume sales. However, regulatory concerns about safety may prompt shifts toward prescription-only formulations.

2. What factors threaten the profitability of sumatriptan succinate?
Generic competition, price erosion, and emergence of alternative treatments reduce profit margins. Also, limitations in formulation innovation impact growth.

3. Are new formulations of naproxen sodium under development?
Yes. Extended-release and topical applications are in R&D pipelines to address safety and efficacy concerns.

4. How is digital health impacting migraine medication sales?
Digital tracking apps improve migraine management, potentially increasing adherence to medications like sumatriptan succinate, though exact market influence remains emerging.

5. What regulatory trends could reshape these markets?
Enhanced safety warnings and approval pathways for new delivery methods may influence sales, prescribing, and manufacturing strategies.

---

References

[1] Market research reports, 2022.
[2] Industry analysis, 2023.
[3] FDA and EMA official publications, 2022-2023.